A Favorable Response to Cisplatin, Pemetrexed and Bevacizumab in Two Cases of Invasive Mucinous Adenocarcinoma Formerly Known as Pneumonic-type Mucinous Bronchioloalveolar Carcinoma
-
- Yamakawa Hideaki
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan Department of Respiratory Medicine, Jikei University School of Medicine, Japan
-
- Takayanagi Noboru
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
-
- Ishiguro Takashi
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
-
- Kagiyama Naho
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
-
- Shimizu Yoshihiko
- Department of Diagnostic Pathology, Saitama Cardiovascular and Respiratory Center, Japan
-
- Sugita Yutaka
- Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan
この論文をさがす
抄録
The leading subtype of lung cancer, adenocarcinoma, received a new classification in 2011 when multifocal, pneumonic-type mucinous tumors, formerly called mucinous bronchioloalveolar carcinomas, were reclassified as "invasive mucinous adenocarcinomas." These tumors appear to be less sensitive to chemotherapy than other non-small cell lung cancers. We herein report two cases of invasive mucinous adenocarcinoma that showed a dramatic radiologic response to combination therapy with cisplatin, pemetrexed and bevacizumab. Recent data suggest that the use of paclitaxel-based chemotherapy is an acceptable therapeutic strategy in cases of invasive mucinous adenocarcinoma. The cases reported here and preclinical findings suggest the therapeutic efficacy of cisplatin, pemetrexed and bevacizumab in treating such tumors.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 52 (24), 2781-2784, 2013
一般社団法人 日本内科学会